Merus (NASDAQ:MRUS) Announces Earnings Results

Merus (NASDAQ:MRUS) released its earnings results on Thursday. The biotechnology company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.48, Zacks reports. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The company had revenue of $9.14 million during the quarter, compared to the consensus estimate of $10.57 million.

Merus Trading Up 1.9 %

Merus stock opened at $47.09 on Friday. The stock has a market cap of $3.22 billion, a PE ratio of -11.92 and a beta of 1.11. The stock has a 50-day moving average price of $42.04 and a 200 day moving average price of $46.80. Merus has a 52 week low of $37.77 and a 52 week high of $61.61.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on MRUS shares. Wells Fargo & Company started coverage on Merus in a report on Friday, February 7th. They issued an “overweight” rating and a $91.00 target price for the company. The Goldman Sachs Group started coverage on Merus in a report on Thursday, November 21st. They issued a “buy” rating and a $73.00 target price for the company. Needham & Company LLC cut their price target on Merus from $85.00 to $83.00 and set a “buy” rating for the company in a research note on Friday. Piper Sandler started coverage on Merus in a research note on Thursday, February 13th. They set an “overweight” rating and a $84.00 price target for the company. Finally, Citigroup lifted their price target on Merus from $89.00 to $97.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. One research analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Merus presently has an average rating of “Buy” and a consensus price target of $85.77.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.